Peter R Elliott

US Patent:

6613541, Sep 2, 2003

Filed:

Oct 19, 1999

Appl. No.:

09/419551

Inventors:

Gopalakrishna R. Vaddi - Hockessin DE
Ross L. Stein - Sudbury MA
Lawrence R. Dick - Natick MA
Vito J. Palombella - Needham MA
Eric S. Lightcap - Natick MA
Peter J. Elliott - Marlboro MA
Julian Adams - Brookline MA
Teresa A. McCormack - Medford MA
Stephen J. Brand - Lincoln MA
Dan R. Burns - Skillman NJ

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C12Q 137

US Classification:

435 23, 435 24, 435 692

Abstract:

The invention relates to methods for measuring proteasome activity in biological samples. More particularly, then invention relates to methods for monitoring drug action following in vivo administration of a proteasome inhibitor. The invention provides methods and kits for monitoring pharmacodynamic drug action and for determining dose regimen for a proteasome inhibitor. The invention also provides methods for determining baseline proteasome activity in a mammal.

US Patent:

8318737, Nov 27, 2012

Filed:

Feb 16, 2011

Appl. No.:

13/028571

Inventors:

Michael Andrew Foley - Chestnut Hill MA, US
Robert Gould - Beverly MA, US
Peter Elliott - Marlboro MA, US
Sam Lee - Newton MA, US

Assignee:

Canthera Therapeutics Inc. - Boston MA
The General Hospital Corporation - Boston MA

International Classification:

A61K 31/5377
A61K 31/45
C07D 413/10
C07D 211/76

US Classification:

5142372, 514327, 544124, 546216

Abstract:

The invention relates to compounds and composition for the treatment and prevention of cancer. The invention also covers all diseases that may be treated by selective modulation of levels of reactive oxygen species in diseased cells versus normal cells. Methods for the preparation and administration of such compositions are also disclosed. A representative compound according to the invention is:.

US Patent:

8349832, Jan 8, 2013

Filed:

Sep 2, 2010

Appl. No.:

12/874306

Inventors:

Michael Andrew Foley - Chestnut Hill MA, US
Robert Gould - Beverly MA, US
Peter Elliott - Marlboro MA, US

Assignee:

Canthera Therapeutics - Boston MA
The Massachusetts General Hospital Corporation - Boston MA

International Classification:

A61K 31/5377
A61K 31/4412
C07D 413/12
C07D 211/86
A61P 35/00

US Classification:

5142355, 514350, 544131, 546298

Abstract:

The invention relates to compounds and composition for the treatment and prevention of cancer. The invention also covers all diseases that may be treated by selective modulation of levels of reactive oxygen species in diseased cells versus normal cells. Methods for the preparation and administration of such compositions are also disclosed.

US Patent:

20010051654, Dec 13, 2001

Filed:

Jan 26, 2001

Appl. No.:

09/770889

Inventors:

Peter Elliott - Marlborough MA, US
Julian Adams - Brookline MA, US
Louis Plamondon - Watertown MA, US

International Classification:

A61K031/365
A61K031/7048

US Classification:

514/450000, 514/028000

Abstract:

This invention is directed to the treatment of inflammatory and autoimmune diseases by administering proteasome inhibitors, ubiquitin pathway inhibitors, agents that interfere with the activation of NF- B via the ubiquitin proteasome pathway, or mixtures thereof. The invention is further directed to the treatment of inflammatory and autoimmune diseases by administering an effective combination of a glucocorticoid and a proteasome inhibitor, ubiquitin pathway inhibitor, agent that interferes with the activation of NF- B via the ubiquitin proteasome pathway, or mixture thereof. Pharmaceutical compositions comprising a combination of a glucocorticoid and a proteasome inhibitor, ubiquitin pathway inhibitor, agent that interferes with the activation of NF- B via the ubiquitin proteasome pathway, or mixture thereof are also contemplated within the scope of the invention.

US Patent:

20010053760, Dec 20, 2001

Filed:

Jul 30, 2001

Appl. No.:

09/919116

Inventors:

Stephen Brand - San Diego CA, US
Alfred Goldberg - Chestnut Hill MA, US
Louis Plamondon - Watertown MA, US
Francois Soucy - Arlington MA, US
Peter Elliott - Marlborough MA, US

International Classification:

A61K038/05
A61K038/03
A61K031/365

US Classification:

514/002000, 514/019000, 514/450000

Abstract:

This invention is directed to treating ischemia by administering proteasome inhibitors, ubiquitin pathway inhibitors, agents that interfere with the activation of NF- B via the ubiquitin proteasome pathway, or mixtures thereof.

US Patent:

20020160947, Oct 31, 2002

Filed:

Apr 2, 2002

Appl. No.:

10/114602

Inventors:

Peter Elliott - Marlborough MA, US
Wayne Hancock - Philadelphia PA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K038/13
A61K031/407
A61K031/4745

US Classification:

514/009000, 514/291000, 514/412000

Abstract:

The invention relates to allograft transplantation. More particularly, the invention relates to prolonging the survival of transplanted allografts. The invention provides a new method for improving allograft survival in a mammal. The method according to the invention provides a synergistic effect between lactacystin or lactacystin analogs and immunosuppressive drugs to prolong the survival of transplanted allografts in a mammal.

US Patent:

20030069189, Apr 10, 2003

Filed:

Apr 8, 2002

Appl. No.:

10/118526

Inventors:

Stephen Brand - San Diego CA, US
Alfred Goldberg - Chestnut Hill MA, US
Louis Plamondon - Watertown MA, US
Francois Soucy - Arlington MA, US
Peter Elliott - Marlborough MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K038/06

US Classification:

514/018000

Abstract:

This invention is directed to treating ischemia by administering proteasome inhibitors, ubiquitin pathway inhibitors, agents that interfere with the activation of NF- B via the ubiquitin proteasome pathway, or mixtures thereof.

US Patent:

20050080075, Apr 14, 2005

Filed:

Aug 25, 2004

Appl. No.:

10/925835

Inventors:

M. Nichols - Boston MA, US
Michael Foley - Chestnut Hill MA, US
Curtis Keith - Boston MA, US
Mahesh Padval - Waltham MA, US
Peter Elliott - Marlboro MA, US

International Classification:

C07D417/02
A61K031/5415

US Classification:

514225500, 514225800, 544042000, 544044000

Abstract:

The invention provides formulations and structural modifications for phenothiazine compounds which result in altered biodistributions, thereby reducing the occurrence of adverse reactions associated with this class of drug.